Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference

Core Insights - Liquidia Corporation is presenting new data on LIQ861 (YUTREPIA™) at the ATS 2025 International Conference, focusing on safety, tolerability, and exploratory efficacy in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) [1][2] Group 1: Product Information - YUTREPIA is an investigational inhaled dry-powder formulation of treprostinil, designed for easy use with a low-effort device [3] - The FDA issued tentative approval for YUTREPIA for PAH and PH-ILD indications in August 2024 [3] - YUTREPIA was developed using Liquidia's PRINT technology, which allows for precise and uniform drug particle creation for enhanced lung deposition [3] Group 2: Clinical Studies - The ASCENT study is an open-label, prospective multicenter trial evaluating the safety and tolerability of dry powder inhaled treprostinil in PH-ILD patients [3] - The INSPIRE study demonstrated the long-term safety and tolerability of LIQ861 in a PAH patient transitioning from parenteral treprostinil [1] - Three posters will be presented at the ATS conference, detailing initial safety and exploratory efficacy data, changes in cardiac effort, and a case study of transitioning from parenteral treprostinil to LIQ861 [2] Group 3: Company Overview - Liquidia Corporation focuses on developing innovative therapies for rare cardiopulmonary diseases, particularly in pulmonary hypertension [4] - The company is also developing L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [4]